BIB vs. ARKG

Last updated Aug 2, 2026

BIB (ProShares Ultra Nasdaq Biotechnology) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both exchange-traded funds - BIB is a Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%), while ARKG is a Health & Biotech Equities fund actively managed by ARK. BIB is passively managed, while ARKG is actively managed. Over the past 10 years, BIB returned 6.95%/yr vs 8.25%/yr for ARKG. Their 0.77 correlation means they have sometimes moved together and sometimes differently. BIB charges 0.95%/yr vs 0.75%/yr for ARKG.

Performance

BIB vs. ARKG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BIB achieves a 21.11% return, which is significantly lower than ARKG's 33.10% return. Over the past 10 years, BIB has underperformed ARKG with an annualized return of 6.95%, while ARKG has yielded a comparatively higher 8.25% annualized return.

BIB

• 1D: -3.70%
• 1M: -9.58%
• 6M: 16.23%
• YTD: 21.11%
• 1Y: 90.29%
• 3Y*: 23.98%
• 5Y*: 0.36%
• 10Y*: 6.95%
• ALL TIME*: 17.28%

ARKG

• 1D: -1.78%
• 1M: -10.14%
• 6M: 26.72%
• YTD: 33.10%
• 1Y: 63.67%
• 3Y*: 1.35%
• 5Y*: -14.38%
• 10Y*: 8.25%
• ALL TIME*: 6.19%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
ARKG ARK Genomic Revolution Multi-Sector ETF	$92.48M	$118.08M	$121.77M
BIB ProShares Ultra Nasdaq Biotechnology	$704.96K	$1.10M	$967.78K

BIB vs. ARKG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BIB ProShares Ultra Nasdaq Biotechnology	21.11%	59.21%	-9.84%	-1.06%	-28.85%	-6.02%	39.79%	46.71%	-24.93%	40.49%
ARKG ARK Genomic Revolution Multi-Sector ETF	33.10%	23.04%	-28.24%	16.22%	-53.90%	-33.92%	180.40%	44.00%	-1.26%	46.61%

Correlation

The correlation between BIB and ARKG is 0.67, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.67
Correlation (3Y) Balances recent behavior with more history.	0.73
Correlation (5Y) Shows whether the relationship held over a longer period.	0.78
Correlation (10Y) Provides a long-term view across more market conditions.	0.79
Correlation (All Time) Calculated using the full available price history since Oct 31, 2014	0.77

The correlation between BIB and ARKG shifts across timeframes, from 0.67 (1 year) to 0.79 (10 years), reflecting how their relationship changes across market environments.

BIB vs. ARKG - Sectors Allocation Comparison

Sectors	BIB	ARKG
Healthcare	57.0%	97.3%
Financial Services	6.1%	0.9%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	2.0%
Utilities	-	-

Return for Risk

BIB vs. ARKG — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

BIB

BIB Risk / Return Rank: 89
BIB Sharpe Ratio Rank: 91
BIB Sortino Ratio Rank: 86
BIB Omega Ratio Rank: 80
BIB Calmar Ratio Rank: 95
BIB Martin Ratio Rank: 91

ARKG

ARKG Risk / Return Rank: 59
ARKG Sharpe Ratio Rank: 62
ARKG Sortino Ratio Rank: 66
ARKG Omega Ratio Rank: 56
ARKG Calmar Ratio Rank: 65
ARKG Martin Ratio Rank: 47

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

BIB vs. ARKG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BIB	ARKG	Difference
Sharpe ratio: Return per unit of total volatility	2.29	1.45	+0.84
Sortino ratio: Return per unit of downside risk	2.87	2.16	+0.71
Omega ratio: Gain probability vs. loss probability	1.34	1.25	+0.09
Calmar ratio: Return relative to maximum drawdown	5.48	2.26	+3.22
Martin ratio: Return relative to average drawdown	15.43	5.42	+10.02

BIB vs. ARKG - Sharpe Ratio Comparison

The current BIB Sharpe Ratio is 2.29, which is higher than the ARKG Sharpe Ratio of 1.45. The chart below compares the historical Sharpe Ratios of BIB and ARKG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

BIB vs. ARKG - Drawdown Comparison

The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for BIB and ARKG.

Drawdown Indicators

	BIB	ARKG	Difference
Max Drawdown Largest peak-to-trough decline	-67.24%	-83.59%	+16.35%
Max Drawdown (1Y) Largest decline over 1 year	-16.92%	-27.51%	+10.59%
Max Drawdown (3Y) Largest decline over 3 years	-45.30%	-46.45%	+1.15%
Max Drawdown (5Y) Largest decline over 5 years	-65.86%	-79.26%	+13.40%
Max Drawdown (10Y) Largest decline over 10 years	-66.20%	-83.59%	+17.39%
Current Drawdown Current decline from peak	-12.04%	-65.50%	+53.46%
Average Drawdown Average peak-to-trough decline	-32.55%	-36.27%	+3.72%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.00%	11.46%	-5.46%

Volatility

BIB vs. ARKG - Volatility Comparison

ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 12.15% compared to ARK Genomic Revolution Multi-Sector ETF (ARKG) at 10.47%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BIB	ARKG	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.15%	10.47%	+1.68%
Volatility (6M) Calculated over the trailing 6-month period	31.41%	31.28%	+0.13%
Volatility (1Y) Calculated over the trailing 1-year period	40.57%	43.11%	-2.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	43.72%	46.17%	-2.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	46.29%	41.44%	+4.85%

BIB vs. ARKG - Expense Ratio Comparison

BIB has a 0.95% expense ratio, which is higher than ARKG's 0.75% expense ratio.

Dividends

BIB vs. ARKG - Dividend Comparison

BIB's dividend yield for the trailing twelve months is around 0.33%, while ARKG has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARKG ARK Genomic Revolution Multi-Sector ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.62%	0.85%	3.14%	0.82%	1.34%
BIB ProShares Ultra Nasdaq Biotechnology	0.33%	0.77%	1.69%	0.07%	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both BIB and ARKG in my portfolio?

BIB and ARKG have a correlation of 0.67, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BIB or ARKG?

BIB has higher volatility (12.15%) compared to ARKG (10.47%). In terms of maximum drawdown, BIB dropped -67.24% vs ARKG's -83.59%.

Which ETF is better, BIB or ARKG?

On 10-year performance, ARKG leads with 8.25% vs 6.95% for BIB. On fees, ARKG is cheaper at 0.75% per year. On volatility, ARKG has been the lower-risk option at 10.47%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, BIB or ARKG?

Over the 10-year period, ARKG has performed better with a 8.25% return vs 6.95%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, BIB or ARKG?

ARKG is cheaper with a 0.75% expense ratio, compared with 0.95% for BIB.

Which ETF pays a higher dividend yield, BIB or ARKG?

BIB has the higher dividend yield at 0.33%, compared with 0.00% for ARKG.

What is the main difference between BIB and ARKG?

BIB is categorized as Leveraged Equities, while ARKG is Health & Biotech Equities. They also come from different issuers: ProShares and ARK. Their fees differ too: 0.95% for BIB and 0.75% for ARKG.

Which has better risk-adjusted returns?

BIB currently has the higher Sharpe Ratio (2.29 vs 1.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.